Nicholson Wealth Management Group LLC Buys 7,000 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Nicholson Wealth Management Group LLC increased its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 0.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,609,283 shares of the company’s stock after purchasing an additional 7,000 shares during the quarter. Perspective Therapeutics comprises about 3.4% of Nicholson Wealth Management Group LLC’s portfolio, making the stock its 2nd biggest position. Nicholson Wealth Management Group LLC’s holdings in Perspective Therapeutics were worth $5,134,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CATX. WealthPlan Investment Management LLC grew its position in Perspective Therapeutics by 18.2% during the 4th quarter. WealthPlan Investment Management LLC now owns 401,049 shares of the company’s stock worth $1,279,000 after purchasing an additional 61,757 shares during the last quarter. Rhumbline Advisers grew its position in Perspective Therapeutics by 4.5% during the 4th quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock worth $303,000 after purchasing an additional 4,075 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in Perspective Therapeutics during the 4th quarter worth $51,000. Koa Wealth Management LLC purchased a new stake in shares of Perspective Therapeutics in the fourth quarter valued at about $83,000. Finally, Wealth Effects LLC boosted its holdings in shares of Perspective Therapeutics by 186.8% in the fourth quarter. Wealth Effects LLC now owns 38,000 shares of the company’s stock valued at $121,000 after acquiring an additional 24,750 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $2.84 on Friday. The company has a 50-day moving average of $3.32 and a two-hundred day moving average of $8.53. Perspective Therapeutics, Inc. has a 12-month low of $2.70 and a 12-month high of $19.05.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a report on Tuesday, January 14th. UBS Group assumed coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective on the stock. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Oppenheimer decreased their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Finally, Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Friday, January 24th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $15.14.

Insiders Place Their Bets

In other news, CEO Johan M. Spoor acquired 8,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was acquired at an average price of $3.77 per share, with a total value of $30,160.00. Following the completion of the transaction, the chief executive officer now directly owns 36,257 shares in the company, valued at approximately $136,688.89. This represents a 28.31 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Heidi Henson acquired 25,975 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was purchased at an average cost of $3.85 per share, with a total value of $100,003.75. Following the transaction, the director now owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 67,570 shares of company stock worth $256,789. Insiders own 3.52% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.